WA
ALNY icon

WPG Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

WPG Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.73K Hold
29
– – 0.01% 808
2026
Q1 		$9.6K Sell
29
-2
-6% -$681 0.01% 689
2025
Q4 		$12.3K Hold
31
– – 0.01% 644
2025
Q3 		$14.1K Sell
31
-11
-26% -$4.48K 0.01% 600
2025
Q2 		$13.7K Sell
42
-5
-11% -$1.38K 0.01% 576
2025
Q1 		$12.7K Buy
47
+8
+21% +$2.06K 0.01% 584
2024
Q4 		$9.18K Buy
+39
New +$10.3K 0.01% 656

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WPG Advisers's ALNY Position: Q2 2026 in Review

WPG Advisers held its Alnylam Pharmaceuticals (ALNY) position steady in Q2 2026 at 29 shares worth $8.73K. The position accounts for 0.01% of the portfolio, ranked #808.

WPG Advisers first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $14.1K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • WPG Advisers held 29 shares of Alnylam Pharmaceuticals worth $8.73K as of Q2 2026.
  • WPG Advisers left its Alnylam Pharmaceuticals share count unchanged in Q2 2026.
  • Alnylam Pharmaceuticals made up 0.01% of WPG Advisers's portfolio in Q2 2026, its #808 holding.
  • WPG Advisers first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • WPG Advisers's Alnylam Pharmaceuticals position peaked at $14.1K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.